.png)
Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Preclinical studies show promise for healing and neuroprotection, but human trials are ongoing or anecdotal
S5 and S6 Tables )
TRIUMPH-1 Results and Clinical Trials The TRIUMPH-1 Phase 3 trials have propelled Retatrutide into the spotlight by revealing significant weight loss results
Or, send us a message online.
This form helps LifeMD-affiliated healthcare providers know more about your weight loss goals and what medications may work the best for you
Identified by CAS Number 2381089-83-2, Retatrutide is widely referenced in metabolic and obesity research literature as the first characterized triple agonist targeting the GIP receptor, GLP-1 receptor, and glucagon receptor (GCGR) simultaneously within a single molecular scaffold
US$ 21.87
US$ 26.12
US$ 20.39
US$ 21.37
US$ 27.88
US$ 26.42
